Methods of treating psoriatic arthritis using il-17 antagonists
AssigneeNovartis AG
InventorsShephard MPOFU, Hanno RICHARDS, Karthinathan THANGAVELU, Matthias MACHACEK
Life of this patent
Estimating the term…
Abstract
The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., psoriatic arthritis, which employ a therapeutically effective amount of an Interleukin-17 (IL-17) antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).
Claims30
A method of treating ankylosing spondylitis in a patient, comprising subcutaneously administering about 150 mg secukinumab to the patient every 4 weeks in a composition comprising:
- a) 150 mg/mL secukinumab;
- b) a sugar;
- c) a surfactant selected from polysorbate 20, polysorbate 40, polysorbate 60, or polysorbate 80;
- and
- d) water;
- wherein the composition has a pH of about 5.5 to about 7.4.
A method of treating psoriatic arthritis in a patient, comprising subcutaneously administering about 150 mg secukinumab to the patient every 4 weeks in a composition comprising:
- a) 150 mg/mL secukinumab;
- b) a sugar;
- c) a surfactant selected from polysorbate 20, polysorbate 40, polysorbate 60, or polysorbate 80;
- and
- d) water;
- wherein the composition has a pH of about 5.5 to about 7.4.
A method of treating ankylosing spondylitis in a patient, comprising subcutaneously administering about 150 mg secukinumab to the patient every 4 weeks in a composition comprising:
- a) 150 mg/mL secukinumab;
- b) a stabilizer selected from sucrose, mannitol, glycine, arginine, or a combination thereof;
- c) a surfactant selected from polysorbate 20, polysorbate 40, polysorbate 60, or polysorbate 80;
- and
- d) water;
- wherein the composition has a pH of about 5.5 to about 7.4;
- and
- wherein the composition is administered every 4 weeks.
A method of treating psoriatic arthritis in a patient, comprising subcutaneously administering about 150 mg secukinumab to the patient every 4 weeks in a composition comprising:
- a) 150 mg/mL secukinumab;
- b) a stabilizer selected from sucrose, mannitol, glycine, arginine, or a combination thereof;
- c) a surfactant selected from polysorbate 20, polysorbate 40, polysorbate 60, or polysorbate 80;
- and
- d) water;
- wherein the composition has a pH of about 5.5 to about 7.4.
Dependencies are inferred from the claim text.